Skye Bioscience, Inc. (SKYE)

Skye Bioscience Statistics

Total Valuation

Skye Bioscience has a market cap or net worth of $28.58 million. The enterprise value is $11.78 million.

Market Cap	28.58M
Enterprise Value	11.78M

Important Dates

The last earnings date was Monday, May 11, 2026, after market close.

Earnings Date	May 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Skye Bioscience has 35.13 million shares outstanding. The number of shares has increased by 0.69% in one year.

Current Share Class	35.13M
Shares Outstanding	35.13M
Shares Change (YoY)	+0.69%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	1.38%
Owned by Institutions (%)	12.00%
Float	22.95M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.17
P/TBV Ratio	3.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.03.

Current Ratio	1.78
Quick Ratio	1.64
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-79,087.51

Financial Efficiency

Return on equity (ROE) is -167.97% and return on invested capital (ROIC) is -107.05%.

Return on Equity (ROE)	-167.97%
Return on Assets (ROA)	-87.70%
Return on Invested Capital (ROIC)	-107.05%
Return on Capital Employed (ROCE)	-655.57%
Weighted Average Cost of Capital (WACC)	20.66%
Revenue Per Employee	n/a
Profits Per Employee	-$4.78M
Employee Count	12
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Skye Bioscience has paid $3,400 in taxes.

Income Tax	3,400
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -57.18% in the last 52 weeks. The beta is 3.02, so Skye Bioscience's price volatility has been higher than the market average.

Beta (5Y)	3.02
52-Week Price Change	-57.18%
50-Day Moving Average	0.77
200-Day Moving Average	1.64
Relative Strength Index (RSI)	48.03
Average Volume (20 Days)	209,197

Short Selling Information

The latest short interest is 1.28 million, so 3.66% of the outstanding shares have been sold short.

Short Interest	1.28M
Short Previous Month	1.46M
Short % of Shares Out	3.66%
Short % of Float	5.60%
Short Ratio (days to cover)	5.82

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-59.08M
Pretax Income	-57.33M
Net Income	-57.33M
EBITDA	-58.36M
EBIT	-59.08M
Earnings Per Share (EPS)	-$1.45

Balance Sheet

The company has $17.11 million in cash and $311,318 in debt, with a net cash position of $16.80 million or $0.48 per share.

Cash & Cash Equivalents	17.11M
Total Debt	311,318
Net Cash	16.80M
Net Cash Per Share	$0.48
Equity (Book Value)	9.01M
Book Value Per Share	0.26
Working Capital	8.16M

Cash Flow

Operating Cash Flow	-42.43M
Capital Expenditures	n/a
Depreciation & Amortization	718,859
Net Borrowing	-71,525
Free Cash Flow	-42.43M
FCF Per Share	-$1.21

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Skye Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.69%
Shareholder Yield	-0.69%
Earnings Yield	-200.60%
FCF Yield	-148.48%

Analyst Forecast

The average price target for Skye Bioscience is $7.71, which is 847.64% higher than the current price. The consensus rating is "Buy".

Price Target	$7.71
Price Target Difference	847.64%
Analyst Consensus	Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:250.

Last Split Date	Sep 8, 2023
Split Type	Reverse
Split Ratio	1:250

Scores

Altman Z-Score	n/a
Piotroski F-Score	1